Brendan J Guercio1, Kaori Sato1, Donna Niedzwiecki1, Xing Ye1, Leonard B Saltz1, Robert J Mayer1, Rex B Mowat1, Renaud Whittom1, Alexander Hantel1, Al Benson1, Daniel Atienza1, Michael Messino1, Hedy Kindler1, Alan Venook1, Frank B Hu1, Shuji Ogino1, Kana Wu1, Walter C Willett1, Edward L Giovannucci1, Jeffrey A Meyerhardt1, Charles S Fuchs2. 1. Brendan J. Guercio, Shuji Ogino, and Edward L. Giovannucci, Harvard Medical School; Kaori Sato, Robert J. Mayer, Shuji Ogino, Jeffrey A. Meyerhardt, and Charles S. Fuchs, Dana-Farber Cancer Institute; Frank B. Hu, Shuji Ogino, Kana Wu, Walter C. Willett, and Edward L. Giovannucci, Harvard T.H. Chan School of Public Health; Shuji Ogino and Edward L. Giovannucci, Brigham and Women's Hospital, Boston, MA; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al Benson, Northwestern University; Hedy Kindler, University of Chicago, Chicago, IL; Daniel Atienza, Virginia Oncology Associates, Norfolk, VA; Donna Niedzwiecki and Xing Ye, Duke University Medical Center, Durham; Michael Messino, Southeast Cancer Control Consortium, Mission Hospitals, Asheville, NC; and Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA. 2. Brendan J. Guercio, Shuji Ogino, and Edward L. Giovannucci, Harvard Medical School; Kaori Sato, Robert J. Mayer, Shuji Ogino, Jeffrey A. Meyerhardt, and Charles S. Fuchs, Dana-Farber Cancer Institute; Frank B. Hu, Shuji Ogino, Kana Wu, Walter C. Willett, and Edward L. Giovannucci, Harvard T.H. Chan School of Public Health; Shuji Ogino and Edward L. Giovannucci, Brigham and Women's Hospital, Boston, MA; Leonard B. Saltz, Memorial Sloan Kettering Cancer Center, New York, NY; Rex B. Mowat, Toledo Community Hospital Oncology Program, Toledo, OH; Renaud Whittom, Hôpital du Sacré-Coeur de Montréal, Montreal, Quebec, Canada; Alexander Hantel, Loyola University Stritch School of Medicine, Naperville; Al Benson, Northwestern University; Hedy Kindler, University of Chicago, Chicago, IL; Daniel Atienza, Virginia Oncology Associates, Norfolk, VA; Donna Niedzwiecki and Xing Ye, Duke University Medical Center, Durham; Michael Messino, Southeast Cancer Control Consortium, Mission Hospitals, Asheville, NC; and Alan Venook, University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA. charles_fuchs@dfci.harvard.edu.
Abstract
PURPOSE: Observational studies have demonstrated increased colon cancer recurrence in states of relative hyperinsulinemia, including sedentary lifestyle, obesity, and increased dietary glycemic load. Greater coffee consumption has been associated with decreased risk of type 2 diabetes and increased insulin sensitivity. The effect of coffee on colon cancer recurrence and survival is unknown. PATIENTS AND METHODS: During and 6 months after adjuvant chemotherapy, 953 patients with stage III colon cancer prospectively reporteddietary intake of caffeinated coffee, decaffeinated coffee, and nonherbal tea, as well as 128 other items. We examined the influence of coffee, nonherbal tea, and caffeine on cancer recurrence and mortality using Cox proportional hazards regression. RESULTS: Patients consuming 4 cups/d or more of total coffee experienced an adjusted hazard ratio (HR) for colon cancer recurrence or mortality of 0.58 (95% CI, 0.34 to 0.99), compared with never drinkers (Ptrend = .002). Patients consuming 4 cups/d or more of caffeinated coffee experienced significantly reduced cancer recurrence or mortality risk compared with abstainers (HR, 0.48; 95% CI, 0.25 to 0.91; Ptrend = .002), and increasing caffeine intake also conferred a significant reduction in cancer recurrence or mortality (HR, 0.66 across extreme quintiles; 95% CI, 0.47 to 0.93; Ptrend = .006). Nonherbal tea and decaffeinated coffee were not associated with patient outcome. The association of total coffee intake with improved outcomes seemed consistent across other predictors of cancer recurrence and mortality. CONCLUSION: Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer.
RCT Entities:
PURPOSE: Observational studies have demonstrated increased colon cancer recurrence in states of relative hyperinsulinemia, including sedentary lifestyle, obesity, and increased dietary glycemic load. Greater coffee consumption has been associated with decreased risk of type 2 diabetes and increased insulin sensitivity. The effect of coffee on colon cancer recurrence and survival is unknown. PATIENTS AND METHODS: During and 6 months after adjuvant chemotherapy, 953 patients with stage III colon cancer prospectively reported dietary intake of caffeinated coffee, decaffeinated coffee, and nonherbal tea, as well as 128 other items. We examined the influence of coffee, nonherbal tea, and caffeine on cancer recurrence and mortality using Cox proportional hazards regression. RESULTS:Patients consuming 4 cups/d or more of total coffee experienced an adjusted hazard ratio (HR) for colon cancer recurrence or mortality of 0.58 (95% CI, 0.34 to 0.99), compared with never drinkers (Ptrend = .002). Patients consuming 4 cups/d or more of caffeinated coffee experienced significantly reduced cancer recurrence or mortality risk compared with abstainers (HR, 0.48; 95% CI, 0.25 to 0.91; Ptrend = .002), and increasing caffeine intake also conferred a significant reduction in cancer recurrence or mortality (HR, 0.66 across extreme quintiles; 95% CI, 0.47 to 0.93; Ptrend = .006). Nonherbal tea and decaffeinated coffee were not associated with patient outcome. The association of total coffee intake with improved outcomes seemed consistent across other predictors of cancer recurrence and mortality. CONCLUSION: Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer.
Authors: Loïc Le Marchand; Hansong Wang; Sabina Rinaldi; Rudolf Kaaks; Thomas M Vogt; Lance Yokochi; Robert Decker Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-05-25 Impact factor: 4.254
Authors: R Kaaks; P Toniolo; A Akhmedkhanov; A Lukanova; C Biessy; H Dechaud; S Rinaldi; A Zeleniuch-Jacquotte; R E Shore; E Riboli Journal: J Natl Cancer Inst Date: 2000-10-04 Impact factor: 13.506
Authors: Brian M Wolpin; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Jennifer A Chan; Kana Wu; Michael N Pollak; Edward L Giovannucci; Charles S Fuchs Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: En Cheng; Fang-Shu Ou; Chao Ma; Donna Spiegelman; Sui Zhang; Xin Zhou; Tiffany M Bainter; Leonard B Saltz; Donna Niedzwiecki; Robert J Mayer; Renaud Whittom; Alexander Hantel; Al Benson; Daniel Atienza; Michael Messino; Hedy Kindler; Edward L Giovannucci; Erin L Van Blarigan; Justin C Brown; Kimmie Ng; Cary P Gross; Jeffrey A Meyerhardt; Charles S Fuchs Journal: J Clin Oncol Date: 2022-01-07 Impact factor: 44.544
Authors: Tomotaka Ugai; Koichiro Haruki; Juha P Väyrynen; Jennifer Borowsky; Kenji Fujiyoshi; Mai Chan Lau; Naohiko Akimoto; Rong Zhong; Junko Kishikawa; Kota Arima; Shan-Shan Shi; Melissa Zhao; Charles S Fuchs; Xuehong Zhang; Marios Giannakis; Mingyang Song; Hongmei Nan; Jeffrey A Meyerhardt; Molin Wang; Jonathan A Nowak; Shuji Ogino Journal: Mayo Clin Proc Date: 2022-01 Impact factor: 11.104
Authors: Ryan H Moy; Alexander Nguyen; Jia Min Loo; Norihiro Yamaguchi; Christina M Kajba; Balaji Santhanam; Benjamin N Ostendorf; Y Gloria Wu; Saeed Tavazoie; Sohail F Tavazoie Journal: Dev Cell Date: 2022-04-28 Impact factor: 13.417
Authors: Stephanie L Schmit; Hedy S Rennert; Gad Rennert; Stephen B Gruber Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-04 Impact factor: 4.254
Authors: Yang Hu; Ming Ding; Chen Yuan; Kana Wu; Stephanie A Smith-Warner; Frank B Hu; Andrew T Chan; Jeffrey A Meyerhardt; Shuji Ogino; Charles S Fuchs; Edward L Giovannucci; Mingyang Song Journal: Gastroenterology Date: 2017-11-20 Impact factor: 22.682